Skip to main navigation
COMPANY
About Us
Executive Team
Board of directors
Scientific Advisory Board
Business Development
Contact Us
SCIENCE
OPTIREACH Technology
Antibody Fragment Technology
NEUROPROTECTIVE APPROACH FOR EYE DISEASES
Publications
PIPELINE
Overview
OCS-01 Diabetic Macular Edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Dry Eye Disease
OCS-02 Uveitis
OCS-05 ACUTE OPTIC NEURITIS
OCS-05 Glaucoma
CAREERS
INVESTORS & MEDIA
Overview
Stock Information
News Releases
Events & Presentations
Earnings Calendar
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
COMPANY
About Us
Executive Team
Board of directors
Scientific Advisory Board
Business Development
Contact Us
SCIENCE
OPTIREACH Technology
Antibody Fragment Technology
NEUROPROTECTIVE APPROACH FOR EYE DISEASES
Publications
PIPELINE
Overview
OCS-01 Diabetic Macular Edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Dry Eye Disease
OCS-02 Uveitis
OCS-05 ACUTE OPTIC NEURITIS
OCS-05 Glaucoma
CAREERS
INVESTORS & MEDIA
Overview
Stock Information
News Releases
Events & Presentations
Earnings Calendar
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
Event Details
Q2 2024 Earnings
Aug 27, 2024
